Answers are grounded in this paper and cite their sources.
Background Chemotherapy plays an important role in management of head and neck cancer; however, its use is frequently associated with adverse drug reactions (ADRs) that may negatively affect. Therefore, monitoring of chemotherapy-related ADRs is essential to improve patient safety and to optimize therapeutic outcomes. Methods A prospective observational study was conducted among head and neck cancer patients receiving chemotherapy at a tertiary care hospital in Central Gujarat. A total of 386 patients were included in study. ADRs were documented through active surveillance and evaluated for causality, severity, and preventability using the WHO–UMC causality assessment scale, Naranjo’s algorithm, Modified Hartwig and Siegel severity scale, and Modified Schumock and Thornton preventability scale. Descriptive analysis was performed using Microsoft Excel. Results Among the 386 patients receiving chemotherapy, 355 patients (91.97%) experienced at least one ADR, resulting in a total of 1508 ADR events. Musculo-skeletal pain-related reactions and gastrointestinal disturbances were most frequently reported ADR categories. The most common individual ADRs included constipation, change in body weight, alopecia, dizziness/fatigue and body pain. Cisplatin-based chemotherapy showed highest proportion of ADR events, followed by paclitaxel with carboplatin. Most ADRs were categorized as probable in causality assessment and were moderate in severity, while a considerable proportion were found to be preventable. Conclusion Chemotherapy-induced ADRs are common among head and neck cancer patients. Continuous monitoring through pharmacovigilance programs is essential to identify ADRs early, improve patient safety, and optimize chemotherapy management.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: